RecallRadar

FDA Drug recall D-1507-2020

Elitek (rasburicase) for injection, 7.5 mg vial, Rx Only Mfd. by Sanofi - Aventis U. S. LLC Bridgewater, NJ, 08807, NDC 0024-5151-75

On 2020-08-26 the FDA classified a Class II recall of Elitek (rasburicase) for injection, 7.5 mg vial, Rx Only Mfd. by Sanofi - Aventis U. S. LLC Bridgewater, NJ, 08807, NDC 0024-5151-75 by Sanofi Aventis U S, citing failed Stability Specifications: Out of Specification result for enzyme activity levels noted during routine stability testing.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1507-2020
ClassificationClass II
Statusongoing
Initiated2020-08-10
Published2020-08-26
Last updated2026-09-13 11:52 UTC
CompanySanofi Aventis U S
DistributionUS

Product

Elitek (rasburicase) for injection, 7.5 mg vial, Rx Only Mfd. by Sanofi - Aventis U. S. LLC Bridgewater, NJ, 08807, NDC 0024-5151-75

Reason

Failed Stability Specifications: Out of Specification result for enzyme activity levels noted during routine stability testing.

Identifiers

ndc0024-5150-10
ndc0024-5154-11
ndc0024-5152-11
ndc0024-5151-75
ndc0024-5155-74
ndc0024-5153-74
code_infoLot #: A9306, Exp 2/28/2022

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1507-2020%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.